Calliditas Net Borrowings from 2010 to 2024
| CALT Stock | USD 39.49 0.14 0.36% |
Net Borrowings | First Reported 2010-12-31 | Previous Quarter 554.4 M | Current Value 582.2 M | Quarterly Volatility 214.3 M |
Check Calliditas Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calliditas Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 30.5 M, Depreciation And Amortization of 17.4 M or Interest Expense of 76.9 M, as well as many indicators such as Price To Sales Ratio of 10.95, Dividend Yield of 0.0 or PTB Ratio of 43.63. Calliditas financial statements analysis is a perfect complement when working with Calliditas Therapeutics Valuation or Volatility modules.
Calliditas | Net Borrowings |
Latest Calliditas Therapeutics' Net Borrowings Growth Pattern
Below is the plot of the Net Borrowings of Calliditas Therapeutics over the last few years. It is the difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period. Calliditas Therapeutics' Net Borrowings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Calliditas Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Borrowings | 10 Years Trend |
|
Net Borrowings |
| Timeline |
Calliditas Net Borrowings Regression Statistics
| Arithmetic Mean | 136,861,498 | |
| Coefficient Of Variation | 156.60 | |
| Mean Deviation | 168,700,598 | |
| Median | 30,000,000 | |
| Standard Deviation | 214,322,111 | |
| Sample Variance | 45934T | |
| Range | 586.1M | |
| R-Value | 0.73 | |
| Mean Square Error | 23444.1T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 34,759,489 | |
| Total Sum of Squares | 643075.5T |
Calliditas Net Borrowings History
About Calliditas Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Calliditas Therapeutics income statement, its balance sheet, and the statement of cash flows. Calliditas Therapeutics investors use historical funamental indicators, such as Calliditas Therapeutics's Net Borrowings, to determine how well the company is positioned to perform in the future. Although Calliditas Therapeutics investors may use each financial statement separately, they are all related. The changes in Calliditas Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Calliditas Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Calliditas Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Calliditas Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Borrowings | 554.4 M | 582.2 M |
Pair Trading with Calliditas Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Calliditas Stock
| 0.54 | FENC | Fennec Pharmaceuticals | PairCorr |
| 0.47 | GLUE | Monte Rosa Therapeutics | PairCorr |
| 0.42 | EXEL | Exelixis | PairCorr |
| 0.42 | IOVA | Iovance Biotherapeutics Downward Rally | PairCorr |
The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.
The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Calliditas Stock Analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.